1-5 of 5
quantitative real-time polymerase chain reaction
Close
Sort by
Journal Articles

MRD in AML: does it already guide therapy decision-making?

Gert Ossenkoppele, Gerrit Jan Schuurhuis
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 356–365.
https://doi.org/10.1182/asheducation-2016.1.356
Published: 2016
Journal Articles

Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment

Eva Hoster, Christiane Pott
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 437–445.
https://doi.org/10.1182/asheducation-2016.1.437
Published: 2016
Journal Articles

Detection and management of minimal residual disease in acute lymphoblastic leukemia

Martin Schrappe
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 244–249.
https://doi.org/10.1182/asheducation-2014.1.244
Published: 2014
Journal Articles

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?

Kendra Sweet, Vivian Oehler
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 184–188.
https://doi.org/10.1182/asheducation-2013.1.184
Published: 2013
Journal Articles

ABL Kinase Inhibitor Therapy for CML: Baseline Assessments and Response Monitoring

Timothy Hughes
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 211–218.
https://doi.org/10.1182/asheducation-2006.1.211
Published: 2006